PT1153024E - 2-amino-6-anilino-purinas e sua utilizacao como medicamentos - Google Patents

2-amino-6-anilino-purinas e sua utilizacao como medicamentos

Info

Publication number
PT1153024E
PT1153024E PT00916840T PT00916840T PT1153024E PT 1153024 E PT1153024 E PT 1153024E PT 00916840 T PT00916840 T PT 00916840T PT 00916840 T PT00916840 T PT 00916840T PT 1153024 E PT1153024 E PT 1153024E
Authority
PT
Portugal
Prior art keywords
amino
purins
aniline
medicines
diseases
Prior art date
Application number
PT00916840T
Other languages
English (en)
Inventor
Furet Dr Pascal
Hans-Georg Capraro
Wolfgang Karl-Diether Brill
Patricia Imbach
Giorgio Caravatti
Jurg Zimmermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1153024E publication Critical patent/PT1153024E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT00916840T 1999-02-18 2000-02-16 2-amino-6-anilino-purinas e sua utilizacao como medicamentos PT1153024E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9903762.4A GB9903762D0 (en) 1999-02-18 1999-02-18 Organic compounds

Publications (1)

Publication Number Publication Date
PT1153024E true PT1153024E (pt) 2004-08-31

Family

ID=10848053

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00916840T PT1153024E (pt) 1999-02-18 2000-02-16 2-amino-6-anilino-purinas e sua utilizacao como medicamentos

Country Status (14)

Country Link
US (1) US6767906B2 (pt)
EP (1) EP1153024B1 (pt)
JP (1) JP2002537300A (pt)
CN (1) CN1183133C (pt)
AT (1) ATE265456T1 (pt)
AU (1) AU3804500A (pt)
BR (1) BR0008365A (pt)
CA (1) CA2360353A1 (pt)
DE (1) DE60010234T2 (pt)
ES (1) ES2219326T3 (pt)
GB (1) GB9903762D0 (pt)
HK (1) HK1042479A1 (pt)
PT (1) PT1153024E (pt)
WO (1) WO2000049018A1 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
AU5438499A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
US7115589B2 (en) * 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
IL159735A0 (en) * 2001-07-09 2004-06-20 Aventis Pharma Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
GB0127615D0 (en) 2001-07-09 2002-01-09 Aventis Pharm Prod Inc Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
AU2003301407B2 (en) * 2002-10-15 2010-04-22 Irm Llc Compositions and methods for inducing osteogenesis
US7589207B2 (en) 2002-12-13 2009-09-15 Smithkline Beecham Corporation Cyclohexyl compounds as CCR5 antagonists
US7160834B2 (en) * 2003-03-18 2007-01-09 Exxonmobil Chemical Patents Inc. Soluble group-10 α-diimine catalyst precursors, catalysts and methods for dimerizing and oligomerizing olefins
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
US20050065171A1 (en) * 2003-06-25 2005-03-24 Shakespeare William C. Substituted purine derivatives
US20050124637A1 (en) * 2003-08-15 2005-06-09 Irm Llc Compounds and compositions as inhibitors of receptor tyrosine kinase activity
ES2398239T3 (es) * 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
JP5321061B2 (ja) 2005-08-11 2013-10-23 アリアド・ファーマシューティカルズ・インコーポレイテッド 不飽和複素環誘導体
CA2623374A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
JP5400388B2 (ja) 2005-12-15 2014-01-29 ライジェル ファーマシューティカルズ， インコーポレイテッド キナーゼインヒビターおよびその利用
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101148449B (zh) * 2006-09-20 2010-08-11 浙江医药股份有限公司新昌制药厂 2-(6-喹啉氨基)-6-环丙氨基-9h-嘌呤成盐的方法
WO2010019967A1 (en) * 2008-08-15 2010-02-18 Georgetown University Fluorescent cdk inhibitors for treatment of cancer
JP5590040B2 (ja) 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
WO2012115575A1 (en) * 2011-02-21 2012-08-30 Biomatcell Ab Derivatives for inducing osteogenic differentiation
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
WO2014123882A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. 2,6,7 substituted purines as hdm2 inhibitors
CN116492347A (zh) * 2013-09-18 2023-07-28 华安医学股份有限公司 一种活化ampk的化合物及其用途
CN106083887B (zh) * 2013-09-18 2018-11-20 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3194572B1 (en) 2014-07-30 2023-10-25 Yeda Research and Development Co. Ltd. Media for culturing pluripotent stem cells
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
CA2996978A1 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP4086257A1 (en) * 2016-09-30 2022-11-09 SRI International Dual clk/cdk1 inhibitors for cancer treatment
AU2017369753A1 (en) * 2016-12-01 2019-07-18 Aptose Biosciences Inc. Fused pyrimidine compounds as BRD4 and JAK2 dual inhibitors and methods for use thereof
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
EP3947382A4 (en) * 2019-03-26 2022-11-23 Academia Sinica COMPOUNDS FOR USE IN THE PHARMACOLOGICAL INDUCTION OF HBF FOR THE TREATMENT OF SICKLE CELL DISEASE AND BETA-THALASSEMIA

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE212535C (pt)
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
CA1340361C (en) 1987-04-24 1999-02-02 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5066655A (en) 1987-04-24 1991-11-19 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
WO1990009178A1 (en) 1989-01-31 1990-08-23 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US5753635A (en) 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
AU4920397A (en) * 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
JP2001516694A (ja) * 1997-08-07 2001-10-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プロテインキナーゼ、ｇプロテイン及びポリメラーゼのプリン阻害剤
AUPO912997A0 (en) 1997-09-11 1997-10-02 Commonwealth Scientific And Industrial Research Organisation Antiviral agents
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines

Also Published As

Publication number Publication date
AU3804500A (en) 2000-09-04
CN1340054A (zh) 2002-03-13
US6767906B2 (en) 2004-07-27
WO2000049018A1 (en) 2000-08-24
DE60010234T2 (de) 2005-04-14
US20020016329A1 (en) 2002-02-07
EP1153024B1 (en) 2004-04-28
CA2360353A1 (en) 2000-08-24
ATE265456T1 (de) 2004-05-15
DE60010234D1 (de) 2004-06-03
JP2002537300A (ja) 2002-11-05
CN1183133C (zh) 2005-01-05
HK1042479A1 (en) 2002-08-16
ES2219326T3 (es) 2004-12-01
BR0008365A (pt) 2001-11-13
EP1153024A1 (en) 2001-11-14
GB9903762D0 (en) 1999-04-14

Similar Documents

Publication Publication Date Title
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
DE50310516D1 (de) Fredericamycin-derivate
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE316077T1 (de) Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
IS6491A (is) Pteridínefnasambönd til meðhöndlunar á sóríasis
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
HK1075450A1 (en) heterocyclic compunds, process for their preparation and pharmaceutical compositions containing thenm and thier use in medicine
ATE323474T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
TR200100637T2 (tr) Yeni doğal ürün türevleri
ATE432936T1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen